Sonesitatug Vedotin Priority Review: FDA Decision on AstraZeneca Gastric Cancer ADC Due Q2 2027
FDA grants priority review to AstraZeneca's CLDN18.2 ADC sonesitatug vedotin for pretreated gastric and GEJ cancer; decision expected Q2 2027.
FDA grants priority review to AstraZeneca's CLDN18.2 ADC sonesitatug vedotin for pretreated gastric and GEJ cancer; decision expected Q2 2027.
FDA approved AstraZeneca and Alexion's Klygefa (gefurulimab) for AChR-positive generalized myasthenia gravis. PREVAIL data, how the weekly nanobody works, REMS rules and rivals.
Datroway ivonescimab trials will start with a Phase III in first-line triple-negative breast cancer in a new AstraZeneca, Daiichi Sankyo and Summit pact.